The real risk I think is here. Not all patients respond to VEGF treatment, and its perhaps not obvious who they are except that they are more likely to have chronic or late stage disease. If by some quirk of fate there is a difference in the patient selection between the last trial and the phase 3 trial which results in the treatment group having a higher proportion of non-responders, that could affect the trial outcome.
price target, page-43
-
- There are more pages in this discussion • 22 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add OPT (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
90.5¢ |
Change
-0.010(1.09%) |
Mkt cap ! $1.114B | |||
| Open | High | Low | Value | Volume |
| 91.5¢ | 91.8¢ | 89.5¢ | $1.036M | 1.140M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 31954 | 89.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 91.5¢ | 71302 | 3 |
View Market Depth
| Last trade - 16.10pm 16/10/2024 (20 minute delay) ? |
| OPT (ASX) Chart |